Can a cancer drug combo fight frailty in HIV?

NCT ID NCT07144293

Ongoing Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether a combination of dasatinib and quercetin (D+Q) can safely improve physical function in 82 older adults with HIV who are frail or prefrail. Participants take D+Q or a placebo in six 2-day cycles over 12 weeks, then are monitored for another 12 weeks. The study measures side effects, walking speed, and balance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dasatinib and quercetin (D+Q)
What this could lead to: If it works, this could point toward a treatment to reduce frailty and improve physical ability in older people with HIV.
What could go wrong: This is a small, early-phase trial with only 82 participants. The treatment may not work or could cause side effects. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Frailty HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGING PROBLEMS FRAILTY HIV PREFRAIL

Contacts and locations

Locations

Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS (Site ID: 107)

Boston, Massachusetts, 02115, United States
Case CRS (Site ID: 2501)

Cleveland, Ohio, 44106, United States
Chapel Hill CRS (Site ID: 3201)

Chapel Hill, North Carolina, 27599, United States
Cincinnati CRS (Site ID: 2401)

Cincinnati, Ohio, 45267-0405, United States
Columbia Physicians & Surgeons (P&S) CRS (Site ID: 30329)

New York, New York, 10032, United States
Greensboro CRS (Site ID: 3203)

Greensboro, North Carolina, 27401, United States
Harbor University of California Los Angeles Center CRS (Site ID: 603)

Torrance, California, 90502, United States
Houston Advancing Research Team CRS (Site ID: 31473)

Houston, Texas, 77030, United States
Massachusetts General Hospital CRS (MGH CRS) (Site ID: 101)

Boston, Massachusetts, 02114, United States
New Jersey Medical School Clinical Research Center CRS (Site ID: 31786)

Newark, New Jersey, 07103, United States
Northwestern University CRS (Site ID: 2701)

Chicago, Illinois, 60611, United States
Ohio State University CRS (Site ID: 2301)

Columbus, Ohio, 43210, United States
Penn Therapeutics CRS (Site ID: 6201)

Philadelphia, Pennsylvania, 19104, United States
UCSD Antiviral Research Center CRS (Site ID: 701)

San Diego, California, 92103, United States
University of California, Los Angeles CARE Center CRS (Site ID: 601)

Los Angeles, California, 90035-4709, United States
University of California, San Francisco HIV/AIDS CRS (Site ID: 801)

San Francisco, California, 94143, United States
University of Colorado Hospital CRS (Site ID: 6101)

Aurora, Colorado, 80045, United States
University of Pittsburgh CRS (Site ID: 1001)

Pittsburgh, Pennsylvania, 15213, United States
University of Rochester Adult HIV Therapeutic Strategies Network CRS (Site ID: 31787)

Rochester, New York, 14642, United States
University of Washington Positive Research CRS (Site ID: 1401)

Seattle, Washington, 98104-9929, United States
Vanderbilt Therapeutics (VT) CRS (Site ID: 3652)

Nashville, Tennessee, 37204, United States
Washington University Therapeutics (WT) CRS (Site ID: 2101)

St Louis, Missouri, 63110-1010, United States
Weill Cornell Chelsea CRS (Site ID: 7804)

New York, New York, 10010, United States
Weill Cornell Uptown CRS (Site ID: 7803)

New York, New York, 10065, United States
Whitman-Walker Institute, Inc. CRS (Site ID: 31791)

Washington D.C., District of Columbia, 20009, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.